Week in Review Terns Raises $80 Million for China Global Development of Drugs Licensed from Lilly

Week in Review: Terns Raises $80 Million for China, Global Development of Drugs Licensed from Lilly

Deals and Financings

Trials and Approvals 

• I-Mab Biopharma of Shanghai received China approval of an IND for its long-acting human interleukin-7 for lymphopenia and cancer;
• Adagene, a Suzhou biopharma, dosed the first patient in a US Phase I trial of its lead candidate, an immunotherapy mAb;
• Bio-Thera Solutions of Guangzhou started a China Phase III trial of its HER2 antibody-drug conjugate in patients with metastatic breast cancer;
• Ark Biosciences, a Shanghai-Suzhou clinical-stage biotech, will release clinical efficacy results from a global trial of a treatment for RSV.

Stock Symbols: (NYSE: LLY) (HK: 1801) (SHA: 603259)

Share this with colleagues:

More From BioPortfolio on "Week in Review: Terns Raises $80 Million for China, Global Development of Drugs Licensed from Lilly"